Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 37
Region China at a glance
Diabetes trend in population
Population with diabetes
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Million
Diabetes growth rate
160
NN Insulin MS
NN OAD MS
bDKK
24-
NN GLP-1 MS
First nine months of
2018
Sales
(mDKK)
YTD
growth²
100%
5%
Long-acting insulin³
619
21%
495%
Premix insulin4
2,870
9%
GLP-1
80%
120
Fast-acting insulin5
1,105
19%
I
125
32.5%1
119
16
Human insulin
2,144
(7%)
60%
Total insulin
6,738
6%
80
12.5%¹
Insulin
40%
GLP-16
388
89%
80
40
20
0
0
2000
2017
2045
Aug
2013
12.5%¹
OAD - 20%
0%
Other diabetes care?
Diabetes care
Obesity (SaxendaⓇ)
Biopharm³
1,284
6%
8,410
8%
163
Aug
2018
Total
8,573
(4%)
8%
China population 2018: ~1.4 billion people and diabetes prevalence
~10.9%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for last 5-year period
Competitor value market share for insulin as of Aug 2018: Sanofi 18%
and Gan & Lee 12%
Competitor value market share for GLP-1 as of Aug 2018: AstraZeneca
17%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Aug, 2018 value figures
2 Percentage change in local currency from YTD Q3 2017 to YTD Q3 2018
3 Comprises TresibaⓇ and Levemir®; 4 Comprises NovoMix®;
5 Comprises NovoRapidⓇ; 6 Comprises Victoza®; 7 Comprises Novo NormⓇ
and needles; 8 Comprises primarily NovoSeven®, NovoEight® and
Norditropin®View entire presentation